Yueh Mei-Fei, Chen Shujuan, Nguyen Nghia, Tukey Robert H
Laboratory of Environmental Toxicology, Department of Pharmacology, University of California, San Diego, La Jolla, California
Laboratory of Environmental Toxicology, Department of Pharmacology, University of California, San Diego, La Jolla, California.
Mol Pharmacol. 2017 May;91(5):545-553. doi: 10.1124/mol.116.107524. Epub 2017 Mar 10.
Hyperbilirubinemia, caused by the accumulation of unconjugated bilirubin, is one of the most common clinical diagnoses in both premature and term newborns. Owing to the fact that bilirubin is metabolized solely through glucuronidation by UDP-glucuronosyltransferase (UGT) 1A1, it is now known that immaturity of UGT1A1, in combination with the overproduction of bilirubin during the developmental stage, acts as a bottleneck to bilirubin elimination and predisposes the infant to high total serum bilirubin levels. Although neonatal jaundice is mostly benign, excessively high levels of serum bilirubin in a small percentage of newborns can cause bilirubin-induced neurologic dysfunction, potentially leading to permanent brain damage, a condition known as Although a large portion of hyperbilirubinemia cases in newborns are associated with hemolytic diseases, we emphasize here the impaired ability of UGT1A1 to eliminate bilirubin that contributes to hyperbilirubinemia-induced neurotoxicity in the developmental stage. As a series of hereditary UGT1A1 mutations have been identified that are associated with UGT1A1 deficiency, new evidence has verified that delayed expression of UGT1A1 during the early stages of neonatal development is a tightly controlled event involving coordinated intrahepatic and extrahepatic regulation. This review recapitulates the progress that has been made in recent years in understanding the causes and physiopathology of severe hyperbilirubinemia, investigating molecular mechanisms underlying bilirubin-induced encephalopathy, and searching for potential therapies for treating pathologic hyperbilirubinemia. Several animal models have been developed to make it possible to examine bilirubin-induced neurotoxicity from multiple directions. Moreover, environmental factors that may alleviate or worsen the condition of hyperbilirubinemia are discussed.
由未结合胆红素积聚引起的高胆红素血症是早产儿和足月儿最常见的临床诊断之一。由于胆红素仅通过尿苷二磷酸葡萄糖醛酸基转移酶(UGT)1A1进行葡萄糖醛酸化代谢,现在已知UGT1A1的不成熟,与发育阶段胆红素的过度产生相结合,成为胆红素消除的瓶颈,并使婴儿易出现高血清总胆红素水平。虽然新生儿黄疸大多是良性的,但一小部分新生儿的血清胆红素水平过高会导致胆红素诱导的神经功能障碍,可能导致永久性脑损伤,这种情况称为 虽然新生儿高胆红素血症的大部分病例与溶血性疾病有关,但我们在此强调UGT1A1消除胆红素的能力受损,这在发育阶段导致了高胆红素血症诱导的神经毒性。由于已鉴定出一系列与UGT1A1缺乏相关的遗传性UGT1A1突变,新证据证实新生儿发育早期UGT1A1的延迟表达是一个受严格控制的事件,涉及肝内和肝外的协调调节。本综述概述了近年来在理解严重高胆红素血症的病因和病理生理学、研究胆红素诱导的脑病的分子机制以及寻找治疗病理性高胆红素血症的潜在疗法方面取得的进展。已经开发了几种动物模型,以便能够从多个方向研究胆红素诱导的神经毒性。此外,还讨论了可能减轻或加重高胆红素血症病情的环境因素。